did point out some difficulties and obstacles that I might face from my friends and colleagues to maintain a good quality journal, and he emphasized that the quality of papers should never be compromised. I followed his advice and, in doing so initially, may have made a few of my friends unhappy; however, during the last 30 years, the Journal of Clinical Immunology has grown, its impact factor continues to increase, and it has become one of the premier journals in clinical immunology.
Recently, I have taken an International project to develop centers of excellence (COE) in primary immunodeficiency (PID) in India. It is estimated that there may be more than 1 million children and adults in India with PID who are not diagnosed and treated. There are few formally trained physicians/scientists in the area of PID, and the diagnostic facilities are limited. During the last 6 months, I have been successful in convincing and securing support from the Minister of Health and Family Welfare, Director of the Indian Council for Medical Research, the Secretary of the Department of Biotechnology in the Ministry of Science and Technology to establish COE in PID in India. The first COE will be in operation by early 2011. I always wanted to give something back to my own country of birth. I am pleased that I now will have time to dedicate my efforts to develop premier institutions in PID in India, works for my charitable foundation (Foundation for Primary Immunodeficiency), and help thousands of patients with PID in India. There will, however, not be any change in my current position at the University of California at Irvine.
During the last 30 years, I had the pleasure of working with associate editors, advisory board members, and a large number of dedicated editorial board members. The success of the journal is largely because of assistance from associate editors, advice from the most outstanding advisory board, and the rigor and fairness with which editorial board members have provided critical reviews of the manuscripts submitted to the journal. I thank you all for the time and efforts, and the quality of reviews that you provided through many years. Since I consider the Journal of Clinical Immunology to be my baby, I leave with some mixed feelings; however, I am pleased that it will be the flagship journal of the Clinical Immunology Society, and the journal will be run by an outstanding editor and a group of dedicated editorial board members.
Good luck to us, and I wish a successful future for the Journal of Clinical Immunology.
Sudhir Gupta, M.D., Ph.D.
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